Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents

Dec 01 2018

• By Brenda Sandburg

Adalimumab monoclonal antibody drug. Anti-inflammatory TNF-alpha inhibitor used in treatment of rheumatoid arthritis, psoriasis, ulcerative colitis, etc. Generic name and stylized antibody.

Related Content

Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says

Apr 11 2018

AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim

Nov 09 2018

AbbVie Hit Harder By EU Humira Biosimilars Than Projected

Nov 02 2018

Related Companies

Pfizer Inc.

AbbVie Inc.

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Viatris Inc.

Novartis AG

Fresenius SE & Co. KGaA

Momenta Pharmaceuticals, Inc.

Celltrion, Inc.

Merck & Co., Inc.

Johnson & Johnson

Biocon, Ltd.

Boehringer Ingelheim GmbH

Additional Topics

United States Biosimilars Commercial Legal Issues Policy BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window